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Overview: We describe preliminary results from the first compre-
hensive, prospective evaluation of SCT-TMA. To expand on the
current literature, the goals are to determine clinical risk factors as-
sociated with the development of TMA and to report renal outcomes
from this significant complication.
Methods: Clinical and laboratory data are being collected on pedi-
atric SCT recipients, beginning 3 weeks prior to conditioning and
continuing for 100 days post-SCT. All pre-SCT patients are ap-
proached for recruitment and chronic dialysis is the only exclusion
criterion. TMA is defined according to published clinical consensus
guidelines as concomitant lactate dehydrogenase (LDH) above the
upper limit of normal, platelet count and hemoglobin below the
lower limit of normal or transfusion support, microangiopathic
changes (schistocytes on peripheral blood smear), and low haptoglo-
bin. All parameters must be noted for two consecutive measurements
after day 0 to be considered positive.
Results:With a goal enrollment of 100 subjects, we have currently
consented 78 subjects and report data on the first 41 patients com-
pleting the study. By univariate analysis, the following risk factors
were associated with TMA patients versus (vs) controls: allogeneic
SCT (100% vs 73%, p 5 0.04), cyclosporine use (93% vs 62%,
p 5 0.03), fludarabine exposure (87% vs 42%, p 5 0.01), GVHD
(47% vs 8%, p 5 0.01), CMV infection (40% vs 4%, p 5 0.01),
BK infection (73% vs 23%, p 5 0.01), and parainfluenza infection
(27% vs 4%, p 5 0.05). Gender, race, radiation exposure, type of
conditioning, busulfan exposure, EBV, adenovirus, HHV6, and in-
fluenza were not associated with TMA. Renal outcomes are shown
in the table. Notably, TMA patients required more post-SCT blood
pressure medications and were more likely to have acute kidney in-
jury and proteinuria by random urinalyses. While not statistically
different, TMA patients trended towards a higher mortality.
Table. Renal Outcomes in TMA
TMA (n 5 15) Control (n 5 26) p-value*Pre-SCT nuclear glomerular
filtration rate (ml/min/1.73m2)111.0 (96.0-156.0)
[67.0-200.0]130.5 (99.5-148.0)
[63.0-181.0]0.60Post-SCT blood pressure
medications (n)3 (2.5-5.5) [1-7] 1 (0.25-3) [0-4] 0.001Cyclosporine level 248.6 (238.5-294.5)
[169.6-386.4]272.1 (204.9-291.1)
[120.2-340.5]0.80Hematuria (>5 red blood
cells per high power field
on at least 2 consecutive
random urines)8/15 (53.3%) 10/26 (38.5%) 0.51Proteinuria ($30 mg/dL on at least
2 consecutive random urines)10/15 (66.7%) 7/26 (26.9%) 0.02Acute kidney injury (doubling
of pre-SCT creatinine)12/15 (80%) 12/26 (46.2%) 0.05Dialysis 1/15 (6.7%) 1/26 (3.8%) 1.00Death 5/15 (33.3%) 2/26 (7.7%) 0.08*From Fisher’s exact test for categorical variables and Wilcoxon Rank
sum for continuous variables; data expressed as n (%) or median
(25th-75th percentile) [range].
Conclusions: Using strict clinical criteria, we prospectively identi-
fied a high incidence (36.6%) of SCT-TMA. Persistent proteinuria
detected by simple urinalyses and hypertension may be clinical
markers for TMA.While kidney injury following SCT is multifacto-
rial, TMA patients had significant evidence of renal dysfunction after
SCT and poor survival, calling for future studies to determine opti-
mal management strategies.83
BK VIREMIA IS ASSOCIATED WITH CYCLOPHOSPHAMIDE USE AND
GRAFT VERSUS HOST DISEASE (GVHD) IN PEDIATRIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION (SCT)
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BK virus infection post-SCT is a common cause of hemorrhagic
cystitis and is diagnosed by demonstrating virus in the urine (viruria).
BK viremia, independent of viruria, was associated with renal dys-
function in our prior retrospective SCT study (Haines HL et al,
BBMT, 2011). Nevertheless, post-SCT, little is known about both
the prevalence of viremia and risk factors associated with BK infec-
tion. Therefore, we assessed the epidemiology of and clinical indica-
tors for the development of post-SCT BK viremia.
Methods: Post hoc analysis of a prospective observational study in
pediatric SCT. Research urinalyses were conducted weekly during
inpatient hospitalization until 100 days post-SCT. Clinical BKmon-
itoring (blood and/or urine) was performed based on these urinalyses
(hematuria) or for acute kidney injury (AKI). After an initial positive
urine test, further monitoring was performed with plasma testing.
Using polymerase chain reaction (PCR) results, patients were di-
vided into two groups: viremia (i1250 copies/ml; lower limit of de-
tection) or no-viremia. Data were analyzed with Fisher’s exact test
and Wilcoxon rank sum.
Results: Of 41 patients completing the prospective study, 20 had
a blood BK PCR checked for hematuria (n 5 13), AKI (n 5 2),
both (n 5 4), or asymptomatic screening (n 5 1). 12/20 (60%) pa-
tients had viremia (viral levels in table). The viremia group, com-
pared to the no-viremia group, was more likely to receive
cyclophosphamide (75% vs 25%, p 5 0.06; median total dose 120
mg/kg in viremia, 200 mg/kg in no-viremia, p5 0.15), ablative con-
ditioning (75% vs 25%, p5 0.06), and develop GVHD (50% vs 0%,
p5 0.04). GVHD (n 5 6) preceded BK viremia in 2, occurred after
viremia in 3, and was concomitant in 1 patient. There was no differ-
ence between the groups in the incidence of hemorrhagic cystitis
(17% viremia vs 37% no-viremia, p 5 0.35) or CMV, EBV, or ade-
novirus infections. There was also no difference in exposure to radi-
ation, cyclosporine, thymoglobulin, tacrolimus, sirolimus,
methylprednisolone, methotrexate, or mycophenolate.
Table. BK Viral Levels
Viremia No-Viremia
(n 5 12) (n 5 8) p-valuePlasma BK level
(copies/ml)4570 (981-26,782) <1250Number of plasma
tests per patient11 (10-15) 5 (1-13) 0.12Urine BK level
(copies/ml)1.9x109
(3.3x108-3.2x109)
1.5x108
(125,841-4.3x109)
0.86Number of urine
tests per patient1 (1-2) 1 (1-2) 0.93Day post-SCTof first
BK plasma test+26 (13-35)* +20 (5-30)* 0.47Day post-SCTof first
viremia
(>1250 copies/ml)+52 (30-72)†Data expressed as median (25th-75th percentile).
*3 patients (1 viremia, 2 no-viremia) had their first BK plasma test after
start of conditioning, but before day 0.
†One patient developed viremia on day -6.
Conclusions: We identified a high prevalence of BK viremia post-
SCT, and again independent of BK viruria. Risk factors for viremia
included cyclophosphamide, ablative conditioning, and GVHD,
which all could predispose to BK infection via immunosuppression
and/or urothelial irritation. BK-dedicated prospective trials are
needed to determine optimal screening and management for BK in-
fection in SCT.
